{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:00:17Z","timestamp":1788210017796,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objectives<\/jats:title>\n            <jats:p>Sirolimus was found to be associated with a better outcome of Graves\u2019 orbitopathy (GO) at 24\u00a0weeks compared to methylprednisolone. We conducted a retrospective study to investigate its efficacy and safety over a longer period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data from 40 consecutive patients with moderate-to-severe, active GO, 20 treated with sirolimus and 20 with methylprednisolone, were collected. Primary outcome: overall outcome (composite evaluation) of GO at 48\u00a0weeks. Secondary outcomes: (1) GO outcome at 24\u00a0weeks, and, at 24 and 48\u00a0weeks: (2) outcome of single eye features; (3) quality of life (GO-QoL); (4) TSH-receptor antibodies; (5) GO relapse at 48\u00a0weeks; (6) adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The overall GO outcome at 48\u00a0weeks did not differ between the two groups (responders: 55% vs 55%). At 24\u00a0weeks, prevalence of responders was greater in sirolimus group (65% vs 25%; P\u2009=\u20090.01). A reduction\u2009\u2265\u20091 point in clinical activity score (CAS) was more frequent in sirolimus patients at 24 (85% vs 40%; P\u2009=\u20090.005) and 48\u00a0weeks (75% vs 60%; P\u2009=\u20090.03). The proportion of GO-QoL responders (appearance subscale) at 24\u00a0weeks was greater in sirolimus group (62.5% vs 26.3%; P\u2009=\u20090.03). No difference was observed for the remaining outcome measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Treatment with sirolimus is followed by a greater overall response of GO compared with methylprednisolone at 24\u00a0weeks, but not at 48\u00a0weeks, when only CAS is affected. A more prolonged period of treatment may be required for a better outcome to be observed over a longer period.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s40618-024-02470-8","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T13:03:02Z","timestamp":1728306182000},"page":"607-618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term outcome of Graves\u2019 orbitopathy following treatment with sirolimus"],"prefix":"10.1007","volume":"48","author":[{"given":"Simone","family":"Comi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lanzolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Novella","family":"Maglionico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Posarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Latrofa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Figus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferruccio","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-116X","authenticated-orcid":false,"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"2470_CR1","doi-asserted-by":"publisher","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML (2020) Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 11:615993","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"10","key":"2470_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn RS (2015) Current insights into the pathogenesis of Graves\u2019 ophthalmopathy. Horm Metab Res 47(10):773\u2013778","journal-title":"Horm Metab Res"},{"issue":"6","key":"2470_CR3","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1210\/jc.2016-1315","volume":"101","author":"CC Krieger","year":"2016","unstructured":"Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH\/IGF-1 receptor cross talk in Graves\u2019 ophthalmopathy pathogenesis. J Clin Endocrinol Metab. 101(6):2340\u20132347","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2470_CR4","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marin\u00f2 M, Vaidya B, Wiersinga WM, EUGOGO \u2020 (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol. 185(4):G43\u2013G67","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2470_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ (2011) Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96(2):320\u2013332","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2470_CR6","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Curr\u00f2 N, Boschi A, Bernard M, Von Arx G, European Group on Graves\u2019 Orbitopathy (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. European Group on Graves\u2019 Orbitopathy. J Clin Endocrinol Metab. 97(12):4454\u20134463","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2470_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000477803","volume":"6","author":"E Sabini","year":"2017","unstructured":"Sabini E, Leo M, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marin\u00f2 M (2017) Does Graves\u2019 orbitopathy ever disappear? Answers to an old question. Eur Thyroid J 6(5):263\u2013270","journal-title":"Eur Thyroid J"},{"issue":"5","key":"2470_CR8","doi-asserted-by":"publisher","first-page":"e2176","DOI":"10.1210\/clinem\/dgab035","volume":"106","author":"G Rotondo Dottore","year":"2021","unstructured":"Rotondo Dottore G, Bucci I, Lanzolla G, Dallan I, Sframeli A, Torregrossa L, Casini G, Basolo F, Figus M, Nardi M, Marcocci C, Marin\u00f2 M (2021) Genetic profiling of orbital fibroblasts from patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 106(5):e2176\u2013e2190","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2470_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, Fleming JC, Fowler BT, Marcocci C, Marin\u00f2 M, Antonelli A, Dailey R, Harris GJ, Eckstein A, Schiffman J, Tang R, Nelson C, Salvi M, Wester S, Sherman JW, Vescio T, Holt RJ, Smith TJ (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352","journal-title":"N Engl J Med"},{"key":"2470_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Kathleen G, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748\u20131761","journal-title":"N Engl J Med"},{"issue":"7","key":"2470_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40618-022-01791-w","volume":"45","author":"L Bartalena","year":"2022","unstructured":"Bartalena L, Marin\u00f2 M, Marcocci C, Tanda ML (2022) Teprotumumab for Graves\u2019 orbitopathy and ototoxicity: moving problems from eyes to ears? J Endocrinol Invest 45(7):1455\u20131457","journal-title":"J Endocrinol Invest"},{"issue":"17","key":"2470_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","volume":"82","author":"T Nie","year":"2022","unstructured":"Nie T, Lamb YN (2022) Teprotumumab: a review in thyroid eye disease. Drugs 82(17):1663\u20131670","journal-title":"Drugs"},{"key":"2470_CR13","unstructured":"Rapamune Prescribing Information. United States Food and Drug Administration. Wyeth Pharmaceuticals, Inc. May 2015. Retrieved 28 May 2016"},{"key":"2470_CR14","unstructured":"Rapamycin. PubChem Compound. National Center for Biotechnology Information. Retrieved 1 August 2016"},{"issue":"3 Suppl","key":"2470_CR15","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","volume":"35","author":"SN Sehgal","year":"2003","unstructured":"Sehgal SN (2003) Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 35(3 Suppl):7S-14S","journal-title":"Transplant Proc"},{"issue":"4","key":"2470_CR16","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1210\/en.2005-1375","volume":"147","author":"AG Gianoukakis","year":"2006","unstructured":"Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ (2006) Immunoglobulin G from patients with Graves\u2019 disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology 147(4):1941\u20131949","journal-title":"Endocrinology"},{"issue":"12","key":"2470_CR17","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170(12):6348\u20136354","journal-title":"J Immunol"},{"issue":"7","key":"2470_CR18","doi-asserted-by":"publisher","first-page":"E1183","DOI":"10.1210\/jc.2013-4182","volume":"99","author":"L Zhang","year":"2014","unstructured":"Zhang L, Grennan-Jones F, Draman MS, Lane C, Morris D, Dayan CM, Tee AR, Ludgate M (2014) Possible targets for nonimmunosuppressive therapy of Graves\u2019 orbitopathy. J Clin Endocrinol Metab 99(7):E1183\u2013E1190","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2470_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4049\/jimmunol.168.2.942","volume":"168","author":"J Pritchard","year":"2002","unstructured":"Pritchard J, Horst N, Cruikshank W, Smith TJ (2002) Igs from patients with Graves\u2019 disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168(2):942\u2013950","journal-title":"J Immunol"},{"issue":"4","key":"2470_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/IOP.0000000000001876","volume":"37","author":"JCP Roos","year":"2021","unstructured":"Roos JCP, Eglitis V, Murthy R (2021) Inhibition of fibrotic contraction by sirolimus (Rapamycin) in an ex vivo model of thyroid eye disease. Ohthalmic Plast Reconstr Surg 37(4):366\u2013371","journal-title":"Ohthalmic Plast Reconstr Surg"},{"issue":"1","key":"2470_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12890-018-0626-4","volume":"18","author":"M Molina-Molina","year":"2018","unstructured":"Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, Llatj\u00f2s R, Escobar I, Sala-Llinas E, Luburich-Hernaiz P, Dorca J (2018) Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulm Med 18(1):63","journal-title":"BMC Pulm Med"},{"issue":"6","key":"2470_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/0194599810397750","volume":"144","author":"A Ghosh","year":"2011","unstructured":"Ghosh A, Malaisrie N, Leahy KP, Singhal S, Einhorn E, Howlett P, Cohen NA, Mirza N (2011) Cellular adaptive inflammation mediates airway granulation in a murine model of subglottic stenosis. Otolaryngol Head Neck Surg 144(6):927\u2013933","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"2470_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033626","volume":"7","author":"G Chen","year":"2012","unstructured":"Chen G, Chen H, Wang C, Peng Y, Sun L, Liu H, Liu F (2012) Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. PLoS One 7(3):e33626","journal-title":"PLoS One"},{"issue":"3","key":"2470_CR24","first-page":"223","volume":"61","author":"SY Yu","year":"2013","unstructured":"Yu SY, Liu L, Li P, Li J (2013) Rapamycin inhibits the mTOR\/ p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy. Thorac Cardiovasc Surg 61(3):223\u2013228","journal-title":"Thorac Cardiovasc Surg"},{"key":"2470_CR25","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41433-019-0340-3","volume":"33","author":"JCP Roos","year":"2019","unstructured":"Roos JCP, Murthy R (2019) Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves\u2019 orbitopathy. Eye (Lond) 33:679\u2013682","journal-title":"Eye (Lond)"},{"key":"2470_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/IOP.0b013e3180500d57","volume":"23","author":"S Chang","year":"2007","unstructured":"Chang S, Perry JD, Kosmorsky GS, Braun WE (2007) Rapamycin for treatment of refractory dysthyroid compressive neuropathy. Ophthalmic Plast Reconstr Surg 23:225\u2013226","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"11","key":"2470_CR27","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","volume":"45","author":"G Lanzolla","year":"2022","unstructured":"Lanzolla G, Maglionico MN, Comi S, Menconi F, Piaggi P, Posarelli C, Figus M, Marcocci C, Marin\u00f2 M (2022) Sirolimus as a second-line treatment for Graves\u2019 orbitopathy. J Endocrinol Invest 45(11):2171\u20132180","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 1","key":"2470_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000510700","volume":"9","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Wiersinga WM (2020) Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves\u2019 orbitopathy. Eur Thyroid J 9(Suppl 1):3\u201316","journal-title":"Eur Thyroid J"},{"issue":"1","key":"2470_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47(1):9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2470_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1136\/bjo.82.7.773","volume":"82","author":"CB Terwee","year":"1998","unstructured":"Terwee CB, Gerding MN, Dekker FW, Prummel MF, Van Der Pol JP, Wiersinga WM (1998) Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL. Br J Ophthalmol 82(7):773\u2013779","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"2470_CR31","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90(9):5234\u20135240","journal-title":"J Clin Endocrinol Metab"},{"key":"2470_CR32","doi-asserted-by":"publisher","first-page":"204201882095833","DOI":"10.1177\/2042018820958335","volume":"11","author":"J L\u00e4ngericht","year":"2020","unstructured":"L\u00e4ngericht J, Kr\u00e4mer I, Kahaly GJ (2020) Glucocorticoids in Graves\u2019 orbitopathy: mechanisms of action and clinical application. Ther Adv Endocrinol Metab 11:2042018820958335","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"2470_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100(2):432\u2013441","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2470_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422\u2013431","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2470_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/thy.2020.0269","volume":"31","author":"G Vannucchi","year":"2021","unstructured":"Vannucchi G, Campi I, Covelli D, Curr\u00f2 N, Lazzaroni E, Palomba A, Soranna D, Zambon A, Fugazzola L, Muller I, Guastella C, Salvi M (2021) Efficacy profile and safety implications of very low dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid 31(5):821\u2013828","journal-title":"Thyroid"},{"key":"2470_CR36","doi-asserted-by":"crossref","unstructured":"Hamed Azzam\u00a0S, Kang\u00a0S, Salvi\u00a0M, Ezra\u00a0DG (2018) Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev 11(11):CD012984","DOI":"10.1002\/14651858.CD012984.pub2"},{"key":"2470_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, Castillo Laguarta JM, Del Estad Cabello A, Gessa Sorroche M, Espa\u00f1a Gregori E, Sales-Sanz M (2018) Tocilizumab in Graves orbitopathy study group efficacy of tocilizumab in patients with moderate-to-severe corticosteroid resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 195:181\u2013190","journal-title":"Am J Ophthalmol."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02470-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-024-02470-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-024-02470-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T10:27:47Z","timestamp":1740997667000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-024-02470-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1007\/s40618-024-02470-8","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. Michele Marin\u00f2 is a member of the Journal of Endocrinological Investigation Editorial Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed according to Institutional guidelines. Approval was not required. All procedure performed in the study involving human participants were in accordance with the ethical standards of the Trust and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the individual participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}